Sage Journals: Discover world-class research

Abstract

Purpose:

An outcomes’ evaluation of a community-based cardiovascular disease (CVD) prevention program in persons with newly diagnosed type 2 diabetes.

Design:

A prospective, observational study.

Setting:

A community-setting in Ireland.

Participants:

Persons with newly diagnosed type 2 diabetes, aged 40 years or older, and 2 or more cardiovascular risk factors.

Intervention:

A 16-week community-based, cardiovascular prevention program, with health promotion seminars, group exercise, and individual consultations, delivered by a multidisciplinary team.

Measures:

Medical, lifestyle, and well-being measures.

Analysis:

Changes in categorical and continuous variables were analyzed using the paired exact test and the t test/Wilcoxin matched-pairs test, respectively.

Results:

In total, 218 persons (134 men) participated, mean age was 59.8 (10.2) years. Completion rate was 75.2% (n = 164). The proportion achieving target glycosylated hemoglobin (HbA_1c) increased from 53% at baseline to 75% (P < .001) at end of program. Systolic and diastolic blood pressures reduced by 8.8 mm Hg (95% CI: −11.2 to −6.4, P < .001) and 5.2 mm Hg (95% CI: −6.9 to −3.5, P < .001), respectively. Mean low-density lipoprotein cholesterol reduced from 2.45 to 2.05 mmol/L (P < .001). Significantly higher proportions met recommended targets in diet (6.9% vs 43.4%, P < .001) and physical activity (9.2% vs 56.6%, P < .001). Psychosocial measures significantly improved at end of program. The majority of improvements were sustained at 1 year.

Conclusion:

Participation in this CVD prevention program was associated with significant improvements in glycemia and CVD risk factors in newly diagnosed patients with type 2 diabetes.

Keywords

type 2 diabetes cardiovascular diseases risk factors community health care evaluation study

Get full access to this article

View all access options for this article.

References

International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium; 2019. http://www.diabetesatlas.org. Accessed February 2020.

Yusuf

Hawken

Ounpuu

, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952.

Holman

Paul

Bethel

, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet. 2000;355(9200):253–259.

Pyorala

Pedersen

Kjekshus

, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care.1997;20(4):614–620.

Gaede

Vedel

Larsen

, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393.

Ali

Bullard

Saaddine

, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613–1624.

Kotseva

De Backer

De Bacquer

, et al; On behalf of the EUROASPIRE investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European society of cardiology ESC-EORP EUROASPIRE V registry [published online ahead of print February 10, 2019]. Eur J Prev Cardiol. 2019;26(8):824–835. doi:10.1177/2047487318825350.

Gaede

Oellgaard

Cartensen

, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the STENO-2 randomised trial. Diabetologia. 2016;59(11):2298–2307.

10.

Murphy

Byrne

Galvin

, et al. Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings. BMJ Open. 2017;7(8):e015135. doi:10.1136/bmjopen-2016-015135

11.

Cosentino

Grant

Aboyans

, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Europ Heart J. 2019;41(10):1–69.

12.

World Health Organization. Global report on diabetes. 2016. http://www.who.int/diabetes/global-report/en/. Accessed February 2020.

13.

Wood

Kotseva

Connolly

, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. 2008;371:1999–2012.

14.

Reeve

Huphreys

Wakerman

. A comprehensive health service evaluation and monitoring framework. Eval Program Plann. 2015;53:91–98.

15.

Gibson

Flaherty

Cormican

, et al. Translating guidelines to practice: findings from a multidisciplinary preventive cardiology programme in the west of Ireland. Eur J Prev Cardiol. 2014;21(3):366–376.

16.

Connolly

Kotseva

Jennings

, et al. Outcomes of an integrated community-based nurse-led cardiovascular disease prevention programme. Heart. 2017;103(11):840–847.

17.

Estruch

Martinez-Gonzalez

Corella

, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145(1):1–11.

18.

Blair

Haskell

, et al. Assessment of habitual physical activity by a seven-day recall in a community survey and controlled experiments. Am J Epidemiol. 1985;122(5):794–804.

19.

Skyes

. Chester step test: resource pack version 3. Chester College of Higher Education; 1998.

20.

Jetté

Sidney

Blümchen

. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. Clin Cardiol. 1990;13:555–565.

21.

Snaith

. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.

22.

Bentsen

Natvig

Winnem

. Questions you didn’t ask? COOP/WONCA Charts in clinical work and research. World organization of colleges, academies and academic associations of general practitioners/family physicists. Fam Pract. 1999;16(2):190–195.

23.

Rabin

Oppe

. EQ-5D-3 L: user guide. Basic information on how to use the EQ-5D-3 L instrument, version 4.0. EUROQoL Group; 2011.

24.

Prochaska

DiClemente

. Self change processes, self-efficacy and decisional balance across five stages of smoking cessation. Prog Clin Biol Res. 1984;156:131–140.

25.

Miller

Rollnick

. Ten things that motivational interviewing is not. Behav Cogn Psychother. 2009;37(2):1240.

26.

Poland

Krupa

McCall

. Settings for health promotion: an analytic framework to guide intervention design and implementation. Heal Promot Pract. 2009;10(4):505–516.

27.

Berra

Miller

Fair

. Cardiovascular disease prevention and disease management: a critical role for nursing. J Cardiopulm Rehabil. 2006;26(4):197–206.

28.

Rydén

Standl

Malgorzata

, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European society for the study of diabetes (EASD). Eur Heart J. 2007;28(1):88–136.

29.

Piepoli

Hoes

Agewell

, et al. ESC scientific document group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381.

30.

Wing

Lang

Wadden

, et al. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486.

31.

Boulé

Haddad

Kenny

, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218–1227.

32.

Madden

. Evidence for the benefit of exercise therapy in patients with type 2 diabetes. Diabetes Metab Syndro Obes. 2013;6:233–239.

33.

American Diabetes Association. Cardiovascular disease and risk management. Section 9. In Standards of Medicine Care in Diabetes-2017. Diabetes Care. 2017;40(suppl.1):S75–S87.

34.

Webb

Dales

Zaccardi

, et al. Intensive versus standard multifactorial cardiovascular risk factor control in screen-controlled outcomes of the ADDITION-Leicester study. Diabetes Metab Rs Rev. 2019;35(3):e3111.

35.

Tan

Avalos

Dineen

, et al. Traveller health: prevalence of diabetes, pre diabetes and the metabolic syndrome. Ir Med J. 2009;102(6):176–178.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.12 MB

Evaluation of a Community-Based Cardiovascular Prevention Program in Patients With Type 2 Diabetes

Abstract

Purpose:

Design:

Setting:

Participants:

Intervention:

Measures:

Analysis:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material